Last edition
News about
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Olatec Therapeutics presented MJFF-funded preclinical data showing its oral NLRP3 inhibitor dapansutrile delivered disease-modifying effects across two translational Parkinson’s disease mouse models.
G Square Backs Serres in Majority Acquisition to Drive Global Growth
G Square, a European healthcare-focused private equity firm investing in high-growth mid-market companies, has signed an agreement to acquire a majority stake in Serres, a global leader in sustainable surgical fluid management solutions.
Lupin Partners with Galenicum to Commercialise Injectable Semaglutide
Global pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Galenicum Health, S.L.U. through its subsidiary, Lupin Atlantis Holdings SA (LAHSA), for finished injectable formulations of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist.
Infinitopes Raises USD 35.1 Million to Advance Precision Cancer Vaccine into First-in-Human Trial
Infinitopes, a clinical-stage biotechnology company developing cancer vaccines, has completed the second close of its seed financing round, raising an additional USD 15.4 million and bringing total funds secured to USD 35.1 million.
EMA Recommends Record 30 Veterinary Medicines for Approval in 2025
The European Medicines Agency (EMA) has released an overview of its key recommendations for 2025 concerning the authorisation and safety monitoring of veterinary medicines.
Bridge to Life Secures FDA De Novo Clearance for VitaSmart HOPE System in Liver Transplantation
Bridge to Life has received FDA De Novo clearance for its VitaSmart HOPE System, creating a new regulatory pathway for hypothermic oxygenated perfusion in US liver transplantation.
Bayer and VUMC Partner to Advance Cardiovascular and Kidney Therapies
The collaboration will focus initially on cardiovascular and kidney diseases, combining Bayer’s drug development expertise with Vanderbilt University Medical Center’s extensive data resources to generate data-driven insights and accelerate the discovery and development of new therapies addressing significant unmet medical needs.
Insilico Medicine and Hygtia Therapeutics have entered a co-development deal for ISM8969, an AI-designed, brain-penetrant NLRP3 inhibitor, with milestone payments of up to USD 66 million.
ImmunityBio Advances FDA Talks on ANKTIVA Resubmission
ImmunityBio said the FDA has requested additional information to potentially support a resubmission of the sBLA for ANKTIVA in BCG-unresponsive papillary bladder cancer, without requiring new clinical trials, with the company planning to submit the data within 30 days.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy